Custom-Made DNA vaccine takes on advanced liver cancer
NCT ID NCT04251117
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a personalized DNA vaccine (GNOS-PV02) combined with an immune booster and the immunotherapy drug pembrolizumab in 36 adults with advanced hepatocellular carcinoma (HCC). The vaccine is custom-made for each patient based on their tumor's unique genetic markers. The goal is to see if this combination can control the cancer and improve immune response. Participants will receive the vaccine and drugs, and researchers will monitor side effects and tumor shrinkage.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HCC are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Auckland Clinical Studies
Auckland, New Zealand
-
Icahn School of Medicine at Mount Sinai
New York, New York, 10029, United States
-
Johns Hopkins Hospital
Baltimore, Maryland, 21287, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- A made-to-order DNA vaccine takes aim at liver cancer's return
- Simple blood test aims to catch liver cancer before It's too late
- Engineered virus takes on liver cancer when standard treatment fails
- Ultrasound vs. MRI: which spots hidden liver cancer better?
- Epigenetic drug may re-sensitize liver tumors to immunotherapy
- New hope for liver cancer patients who failed immunotherapy?